SalioGen Therapeutics, an organization that raised $135 million to expand a brand new gene-editing era, has instituted standard layoffs and is scaling again its ambitions, in line with an individual acquainted with the location and worker posts on social media.
It’s the most recent in a chain of retrenchments via high-profile gene-editing corporations. A spokesperson for SalioGen declined to remark.
Introduced in 2021, SalioGen used to be amongst a bunch of recent startups growing era for putting full-length genes into sufferers — a feat that may’t readily be achieved with older approaches in accordance with the gene-editing era CRISPR.
STAT+ Unique Tale
Have already got an account? Log in
This newsletter is unique to STAT+ subscribers
Free up this text — plus day-to-day protection and research of the biotech sector — via subscribing to STAT+.
Have already got an account? Log in
Person plans
Staff plans
View All Plans
To learn the remainder of this tale subscribe to STAT+.
Subscribe
